SEC Comment Letter for VERTEX PHARMACEUTICALS (VRTX) — Apr 15, 2010
VERTEX PHARMACEUTICALS INC / MA (VRTX) (CIK 0000875320)
Date: April 15, 2010 · CIK: 0000875320 · Accession: 0000000000-10-020719
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-19319
Letter
Mail Stop 4720 April 15, 2010 Mr. Joshua Boger Chief Executive Officer Vertex Pharmaceuticals Incorporated 130 Waverly Street Cambridge, MA 02139-4242 Re: Vertex Pharmaceuticals Incorporated Form 10-K for the Period Ended December 31, 2008 Definitive Proxy Statement on Schedule 14A filed April 8, 2009 Response filed March 31, 2010 File No. 000-19319
Dear Mr. Boger: We have completed our review of your Form 10-K and related filings and have no further comments at this time. S i n c e r e l y ,
J e f f r e y P . R i e d l e r A s s i s t a n t D i r e c t o r
Show Raw Text
Mail Stop 4720
April 15, 2010
Mr. Joshua Boger Chief Executive Officer Vertex Pharmaceuticals Incorporated 130 Waverly Street Cambridge, MA 02139-4242
Re: Vertex Pharmaceuticals Incorporated
Form 10-K for the Period Ended December 31, 2008 Definitive Proxy Statement on Schedule 14A filed April 8, 2009
Response filed March 31, 2010 File No. 000-19319
Dear Mr. Boger:
We have completed our review of your Form 10-K and related filings and have no
further comments at this time. S i n c e r e l y ,
J e f f r e y P . R i e d l e r A s s i s t a n t D i r e c t o r